COPA and urinary bladder carcinoma: In this study, in order to find novel targets to enhance the sensitivity of erdafitinib therapy and explore the molecular mechanism underlying erdafitinib resistance, we performed genome‐wide CRISPR screen and found that sgRNAs of COPA were significantly absent in erdafitinib‐treated bladder cancer cells.